Suzanne Egyhazi Brage

About me
Publications
Public outreach and news

About me

I have a PhD in experimental oncology. My main focus is to find novel
biomarkers for durable benefit from targeted therapies and immunotherapies
and novel targets to overcome drug resistance in cutaneous malignant
melanoma.

Articles

Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930
Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and Tolerability
Backlund E; Grozman V; Brage SE; Lewensohn R; Lindberg K; Helgadottir H
Article: CANCERS. 2022;14(15):3587
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hoiom V; Brage SE
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: ACTA ONCOLOGICA. 2022;61(1):14-21
A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma
Falkenius J; Keskitalo J; Kanter L; Johansson H; Hoiom V; Hansson J; Brage SE
Article: GENETICS IN MEDICINE. 2022;24(1):157-169
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
Yang M; Johnsson P; Brautigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engstrom PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Hoiom V
Article: SCIENTIFIC REPORTS. 2021;11(1):11023
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
Article: CANCER RESEARCH. 2021;81(9):2545-2555
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Karlsson MJ; Svedman FC; Tebani A; Kotol D; Hoiom V; Fagerberg L; Edfors F; Uhlen M; Brage SE; Maddalo G
Article: CELL DEATH & DISEASE. 2020;11(10):882
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
Das I; Chen H; Maddalo G; Tuominen R; Rebecca VW; Herlyn M; Hansson J; Davies MA; Brage SE
Article: MELANOMA RESEARCH. 2020;30(5):443-454
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
Vidarsdottir L; Fernandes RV; Zachariadis V; Das I; Edsbacker E; Sigvaldadottir I; Azimi A; Hoiom V; Hansson J; Grander D; Egyhazi Brage S; Pokrovskaja Tamm K
Article: CELL DEATH AND DIFFERENTIATION. 2020;27(7):2081-2098
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Das I; Gad H; Braeutigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Rajagopal V; Hansson J; Helleday T; Brage SE; Berglund UW
Article: CELL DEATH & DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: MOLECULAR SYSTEMS BIOLOGY. 2018;14(3):e7858
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi A; Caramuta S; Seashore-Ludlow B; Bostrom J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Brage SE; Altun M; Uhlen M; Maddalo G
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELLULAR ONCOLOGY. 2017;40(6):631-638
ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Article: CELL DEATH & DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: BMC CANCER. 2017;17(1):584
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
Falkenius J; Johansson H; Tuominen R; Stolt MF; Hansson J; Brage SE
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: CELL REPORTS. 2016;15(9):2000-2011
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Georgoudaki A-M; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Ostling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MCI
Article: CLINICAL CANCER RESEARCH. 2016;22(1):146-157
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Kimbung S; Johansson I; Danielsson A; Veerla S; Brage SE; Stolt MF; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmstrom P-O; Soderberg M; Walz TM; Ferno M; Hatschek T; Hedenfalk I
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(12):2844-2853
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Johansson CH; Linden D; Johansson H; Stolt MF; Walker C; Snowden H; Newton-Bishop J; Hansson J; Brage SE
Article: ANNALS OF ONCOLOGY. 2015;26(1):81-88
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2014;24(8):1389-1394
Metabolic Markers and HSP60 in Chemonaive Serous Solid Ovarian Cancer Versus Ascites
Hjerpe E; Brage SE; Stolt MF; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MATRIX BIOLOGY. 2014;38:69-83
Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146)
Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Brage SE; Hansson J; Patarroyo M
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Azimi A; Pernemalm M; Stolt MF; Hansson J; Lehtio J; Brage SE; Johansson CH
Journal article: ANNALS OF ONCOLOGY. 2014;25:i5
12O Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival
Tobin NP; Harrell JC; Brage SE; Stolt MF; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: MELANOMA RESEARCH. 2013;23(6):452-460
High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Brage SE
Article: BMC CLINICAL PATHOLOGY. 2013;13(1):30
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
Hjerpe E; Brage SE; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MELANOMA RESEARCH. 2013;23(5):360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Johansson CH; Azimi A; Stolt MF; Shojaee S; Wiberg H; Grafstrom E; Hansson J; Brage SE
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(3):448-455
HSP60 Predicts Survival in Advanced Serous Ovarian Cancer
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(12):2809-2817
High Frequency of p16 ^INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson A; Tuominen R; Grafstrom E; Hansson J; Egyhazi S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(8):2062-2070
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta S; Egyhazi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui W-O
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: PIGMENT CELL & MELANOMA RESEARCH. 2009;22(2):196-204
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Hoiom V; Tuominen R; Kaller M; Linden D; Ahmadian A; Mansson-Brahme E; Egyhazi S; Sjoberg K; Lundeberg J; Hansson J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(4):526-534
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu L-A; Zerba KE; Lee H; Clark E; Galbraith S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(11):2696-2704
Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
Jovanovic B; Kroeckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
Article: MOLECULAR CANCER THERAPEUTICS. 2008;7(9):2876-2883
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Smalley KSM; Lioni M; Palma MD; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Article: CANCER RESEARCH. 2007;67(19):9006-9012
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: MELANOMA RESEARCH. 2006;16(6):471-478
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Edlundh-Rose E; Egyhazi S; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Article: CLINICAL CHEMISTRY. 2005;51(12):2388-2391
Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing
Käller M; Tuominen R; Ahmadian A; Magnusson V; Egyhazi S; Hansson J; Lundeberg J
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: BREAST CANCER RESEARCH. 2005;7(6):R953-R964
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523
O⁶-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: HUMAN MUTATION. 2002;20(5):408-409
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019
Immunohistochemical analysis of DNA mismatch repair protein and O⁶-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342
Analysis of O⁶-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: CARCINOGENESIS. 1997;18(10):1889-1895
O-6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro
Liu Y; Egyhazi S; Hansson J; Bhide SV; Kulkarni PS; Grafstrom RC
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452
Role of O-6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line
Egyhazi S; Edgren MR; Hansson J; Krockel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134
Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases
Egyhazi S; Margison GP; Hansson J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(13):2319-2326
Analysis of O-6 methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
Hansson J; Martenhed G; Egyhazi S; Tani E; Platz A
Article: ACTA ONCOLOGICA. 1996;35(6):683-690
Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency
Hansson J; Edgren MR; Egyhazi S; Hao XY; Mannervik B; Ringborg U
Article: ANTI-CANCER DRUGS. 1995;6(5):657-668
APOPTOSIS AND C-JUN INDUCTION BY CISPLATIN IN A HUMAN-MELANOMA CELL-LINE AND A DRUG-RESISTANT DAUGHTER CELL-LINE
ZHAO R; RABO YB; EGYHAZI S; ANDERSSON A; EDGREN MR; LINDER S; HANSSON J
Journal article: CANCER RESEARCH. 1993;53(18):4257-4261
CONTRIBUTION OF GLUTATHIONE TRANSFERASE M3-3 TO 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA RESISTANCE IN A HUMAN NONSMALL CELL LUNG-CANCER CELL-LINE
BERHANE K; HAO XY; EGYHAZI S; HANSSON J; RINGBORG U; MANNERVIK B
Journal article: EUROPEAN JOURNAL OF CANCER. 1991;27(12):1658-1662
CARMUSTINE-INDUCED TOXICITY, DNA CROSS-LINKING AND O6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY IN 2 HUMAN LUNG-CANCER CELL-LINES
EGYHAZI S; BERGH J; HANSSON J; KARRAN P; RINGBORG U
Show more

About me

Articles

News from KI

Events from KI